Clinicians have obligations of justice when treating patients, which can lead to difficult decisions on how to ethically allocate limited resources to patients as a whole, said Jacqueline Glover, PhD, professor in the Department of Pediatrics and the Center for Bioethics and Humanities at the University of Colorado Denver.
Clinicians have obligations of justice when treating patients, which can lead to difficult decisions on how to ethically allocate limited resources to patients as a whole, said Jacqueline Glover, PhD, professor in the Department of Pediatrics and the Center for Bioethics and Humanities at the University of Colorado Denver.
Transcript (slightly modified)
When considering an ethical framework for healthcare, what is the physician role regarding costs?
We think about clinicians as professionals, as having role-specific obligations, and it’s never part of a doctor’s, for example, role to consider costs. We want our clinicians to be gatekeepers, but only gatekeepers that swing the door maximally open. They should only consider one patient at a time, and never cost.
I think that’s not true. I think healthcare professionals have obligations of justice, just like you and I have obligations of justice, uncontrolled spending by some puts at risk the availability of some other things, or the very same thing, to others. Clinicians have obligations of justice because we all do.
We also think that the only benefits are on the side of receiving the drug, and that’s not necessarily true. High-cost drugs, not only with the side effects of any drug, but high-cost drugs may not have good outcomes because they’re so expensive. Patients who can’t afford them may start the treatment later, may not take the drug, may not be as compliant, and they may stop taking the drug because of cost.
So, healthcare professionals have obligations to consider patients’ benefit, but also obligations of justice to consider their patients altogether. Human needs are limitless, but our ability to respond to those needs are limited. Our resources are limited, and so cost is an ethical concern, because we have to figure out how best to use our limited resources on behalf of patients and on behalf of all the patients together, what we call the common good.
If we thought of time instead of cost, we don’t expect our doctors to spend all of their time with us. We realize that physicians, nurses, pharmacists have obligations to other patients, so we recognize that with time allocation. It’s the same thing for allocation of cost.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More